Silicon Therapeutics Leadership

Lanny co-founded Silicon Therapeutics and handles the firms day to day operations as well as partnership and financing initiatives. He has spent his entire career in the healthcare sector working across a number of industries including drug discovery, CRO, investment banking, consulting, venture capital, private equity and non-profits. He started his career on Wall Street with Deutsche Bank Securities where he focused on Healthcare M&A and financings and was most recently a Venture Partner at Chengwei. He received his Bachelors of Science in Economics from Trinity College in Hartford, CT.

Humphrey Gardner is the CMO of Silicon Therapeutics. He joined Silicon from Evelo Biosciences, where he served as Chief of Medical Oncology and led oncology discovery as well as the IND and clinical development of their first microbial cancer immune therapy. Previously, he served as Vice President of Early Clinical Development in both Infection and in Oncology at AstraZeneca, and as Senior Vice President of Clinical Development at Karyopharm. Prior to these appointments, he led the Oncology Translational Laboratories at Novartis, and various discovery and translational programs at Biogen. Before joining industry, Humphrey was an Assistant Professor of Cell Biology at The Scripps Research Institute. Humphrey obtained his BA in Biochemistry and his MB, BChir, at the University of Cambridge, UK. He did his specialty training in Anatomic Pathology at the Beth Israel Hospital, Harvard Medical School. He completed his postdoctoral fellowship at the Whitehead Institute in the laboratory of Professor Rudolf Jaenisch. Humphrey has over 100 publications and patents in fields including oncology, neuroscience, rheumatology, and diagnostics, and additionally holds an MS in Bioinformatics from Brandeis University.

Huafeng Xu are a Chief Technology Officer at Silicon Therapeutics and are based in New York City, New York. They have worked as Technology Strategy Advisor at Bevscout; Research Scientist at Johnson & Johnson; and Research Scientist at 3-DIMENSIONAL PHARMACEUTICALS, INC.. Huafeng studied at Columbia University between 1997 and 2001 and Beijing University between 1992 and 1997.

Dr. Winter has held research leadership positions in pharmaceutical companies and emerging biotechnology firms over the past 15 years. During that time, he has delivered ten targeted cancer therapies into clinical development. He joined Sanofi in 2013 as Sanofi Oncology’s Head of Discovery Biology and became site lead in 2015. He joined Sanofi from Blueprint Medicines, where he served as Head of Biology. The first biologist recruited to Blueprint, Dr. Winter built an outstanding interdisciplinary team and led the company’s first drug discovery project, a first-in-class FGFR4 inhibitor for genomically-defined liver cancer. Prior to Blueprint, Dr. Winter held senior research positions at Merck Research Laboratories and Exelixis. He received a PhD in Biochemistry & Molecular Biophysics from Columbia University and was a post-doctoral fellow at Stanford University in the Department of Biological Sciences.

Pamela Carroll is a Chief Business Officer at Silicon Therapeutics.

Woody Sherman is a thought leader in molecular simulations and computer-aided drug design, with over 80 publications covering novel methods and applications. He received his B.S. in Physical Chemistry from the University of California at Santa Barbara where he studied nonlinear optical properties of organic polymers using computational quantum mechanics methods. He completed his Ph.D. at MIT working in Professor Bruce Tidor’s lab where he examined the role of electrostatics in protein-ligand binding and implemented a novel method for optimizing ligand binding specificity across a panel of targets. While in graduate school he completed an internship at Biogen where he helped develop novel methods to enhance antibody affinity through electrostatic charge optimization, resulting in a publication and patent. At Schrödinger, he headed the Applications Science team and was involved in research, product development, methods development, and the deployment of Python-based tools. He also worked closely with Pharma partners on research projects and collaborations. Woody has published on a broad range of topics, including induced-fit docking, ensemble docking, molecular dynamics, free energy simulations, protein design, small molecule optimization, cheminformatics, hybrid ligand/structure-based methods, charge optimization, pharmacophore modeling, and more. He is a reviewer for many top journals related to computational chemistry and drug design and is on the Editorial Board of both Chemical Biology & Drug Design and Journal of Chemical Information and Modeling.Specialties: Molecular modeling, induced-fit docking, ensemble docking, molecular dynamics, enhanced sampling methods, free energy simulations, protein design, small molecule optimization, cheminformatics, hybrid ligand/structure-based methods, charge optimization, pharmacophore modeling, scaffold hopping, conformational search, quantum mechanics.

Lanny co-founded Silicon Therapeutics and handles the firms day to day operations as well as partnership and financing initiatives. He has spent his entire career in the healthcare sector working across a number of industries including drug discovery, CRO, investment banking, consulting, venture capital, private equity and non-profits. He started his career on Wall Street with Deutsche Bank Securities where he focused on Healthcare M&A and financings and was most recently a Venture Partner at Chengwei. He received his Bachelors of Science in Economics from Trinity College in Hartford, CT.

Lanny co-founded Silicon Therapeutics and handles the firms day to day operations as well as partnership and financing initiatives. He has spent his entire career in the healthcare sector working across a number of industries including drug discovery, CRO, investment banking, consulting, venture capital, private equity and non-profits. He started his career on Wall Street with Deutsche Bank Securities where he focused on Healthcare M&A and financings and was most recently a Venture Partner at Chengwei. He received his Bachelors of Science in Economics from Trinity College in Hartford, CT.